Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
GPR160 Biologics Sequence Review Report 2026: Probable G protein-coupled receptor 160 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of GPR160 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
GPR132 Biologics Sequence Review Report 2026: Probable G protein-coupled receptor 132 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of GPR132 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
GPR148 Biologics Sequence Review Report 2026: Probable G protein-coupled receptor 148 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of GPR148 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
GPR141 Biologics Sequence Review Report 2026: Probable G protein-coupled receptor 141 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of GPR141 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
GPR139 Biologics Sequence Review Report 2026: Probable G protein-coupled receptor 139 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of GPR139 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
ADAMTS8 Biologics Sequence Review Report 2026: A disintegrin and metalloproteinase with thrombospondin motifs 8 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of ADAMTS8 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
GPR101 Biologics Sequence Review Report 2026: Probable G protein-coupled receptor 101 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of GPR101 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
ADAM8 Biologics Sequence Review Report 2026: Disintegrin and metalloproteinase domain-containing protein 8 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of ADAM8 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
ADAM7 Biologics Sequence Review Report 2026: Disintegrin and metalloproteinase domain-containing protein 7 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of ADAM7 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
ADAM32 Biologics Sequence Review Report 2026: Disintegrin and metalloproteinase domain-containing protein 32 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of ADAM32 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
ADAM33 Biologics Sequence Review Report 2026: Disintegrin and metalloproteinase domain-containing protein 33 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of ADAM33 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
ADAM5 Biologics Sequence Review Report 2026: Putative disintegrin and metalloproteinase domain-containing protein 5 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of ADAM5 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.